Motilal Oswal: Jubilant Life - Generics Business, Better Profitability In LSI Lead Core Performance
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Jubilant Life Sciences Ltd. delivered higher-than-expected Q2 FY21 earnings, led by better traction in 1) the contract manufacturing organization/generics category in the pharma segment and 2) the life science chemical category in the life science ingredient segment.
The Remdesivir launch further supported growth in the pharma segment. However, we maintain our earnings estimate for FY21/FY22, factoring in Covid-19-led prolonged weakness in the Radiopharma segment.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.